Favorite Abstracts from the 2016 ACR Annual Meeting

Journal Club #15: Favorite Abstracts from the 2016 ACR Annual Meeting

640px-tnf-alpha

The next session of #RheumJC will be Wednesday, December 14. We’ll be discussing four of your favorite abstracts from the 2016 ACR Annual Meeting based on your votes from our recent poll.

The abstracts we’ll be discussing are:

Abstract 911 – Efficacy and Safety of Tocilizumab in Patients with Giant Cell Arteritis: Primary and Secondary Outcomes from a Phase 3, Randomized, Double-Blind, Placebo-Controlled Trial. (48%, 14 Votes)

Abstract 1955 – Rituximab Versus Azathioprine to Maintain Remission of ANCA-Associated Vasculitides (MAINRITSAN): Follow-up at 60 Months (41%, 12 Votes)

Abstract 3028 – A Single Infusion of Rituximab Delays the Onset of Arthritis in Subjects at High Risk of Developing RA. (38%, 11 Votes)

Abstract 1725 – Combination Therapy of Apremilast and Biologic Agent As a Safe Option of Psoriatic Arthritis and Psoriasis (34%, 10 Votes)

—

If you’re new to #RheumJC, take a look at our Intro to Twitter page or our Journal Club Getting Started Guide.

We strongly suggest using the website tchat.io as the best way to participate in the chat by typing in the #RheumJC hashtag to join the discussion.

As always:

  1. Please remember to try to stay on topic whenever possible.
  2. Be polite and courteous.
  3. Do not violate HIPAA.

We welcome suggestions for future articles for discussion. Please send your suggestions by Direct Message on Twitter to @RheumJC or email us at rheumjc@rheumjc.com.

 

 

Poll: What #ACR16 abstracts should we discuss for the next journal club?

Polls

acr16-posterHope everyone had a great time at #ACR16! (In real life or virtually on Twitter)

Greetings and Happy Holidays #RheumJC friends!

For our next session of #RheumJC, we’ll be discussing some of our favorite abstracts from #ACR16. Since we were only able to narrow our list down to 9 abstracts among our team, we’re polling you to decide which abstracts we’ll be discussing for the next journal club.

Also, in hopes of increasing everyone’s ability to participate, we’re also polling on what day of the week and times that work best for you. Over the next year of #RheumJC, we’ll likely plan on mixing up the day of the week and time so that over time everyone has an opportunity to participate.

If you would like to see the full abstract, please check acrabstracts.org (unfortunately, our polling plugin doesn’t allow links).

What #ACR16 abstracts should #RheumJC discuss for the next journal club? (Choose up to 4)

  • 911 - Efficacy and Safety of Tocilizumab in Patients with Giant Cell Arteritis: Primary and Secondary Outcomes from a Phase 3, Randomized, Double-Blind, Placebo-Controlled Trial. (18%, 14 Votes)
  • 1955 - Rituximab Versus Azathioprine to Maintain Remission of ANCA-Associated Vasculitides (MAINRITSAN): Follow-up at 60 Months (16%, 12 Votes)
  • 3028 - A Single Infusion of Rituximab Delays the Onset of Arthritis in Subjects at High Risk of Developing RA. (14%, 11 Votes)
  • 1725 - Combination Therapy of Apremilast and Biologic Agent As a Safe Option of Psoriatic Arthritis and Psoriasis (13%, 10 Votes)
  • 3225 - Dual Cytokine Inhibition with ABT-122, a Tnf– and IL-17–Targeted Dual Variable Domain Immunoglobulin (DVD-Ig™): Results from a 24-Week Open-Label Extension Study in Patients with RA (12%, 9 Votes)
  • 3169 - Diagnostic Value of Ultrasound for the Diagnosis of Gout in a Prospective Cross-Sectional Study (9%, 7 Votes)
  • 1957 - No Increased Risk of Chronic Kidney Disease with Allopurinol Use (8%, 6 Votes)
  • 86 - Optimizing the Efficiency of Patient Data Capture Using Smartphone Technology: Evaluation of the Correlation Between Promis Instruments for PRO Data Capture (5%, 4 Votes)
  • 2987 - Comparison of Certolizumab Pegol Versus Adalimumab: 2 Year Efficacy and Safety Results from a Superiority, Investigator-Blind, Head-to-Head Study (4%, 3 Votes)

Total Voters: 29

Loading ... Loading ...

What day of the week should we hold #RheumJC? (choose all days that would work for you)

  • Wednesday (19%, 9 Votes)
  • Thursday (19%, 9 Votes)
  • Tuesday (15%, 7 Votes)
  • Sunday (13%, 6 Votes)
  • Friday (13%, 6 Votes)
  • Monday (11%, 5 Votes)
  • Saturday (11%, 5 Votes)

Total Voters: 19

Loading ... Loading ...

What time of day would best allow you to participate in #RheumJC? (choose all times that would work for you)

  • 8p-10p Eastern / 1a-3a GMT (22%, 8 Votes)
  • 2p-4p Eastern / 7p-9p GMT (19%, 7 Votes)
  • 4p-6p Eastern / 9p-11p GMT (16%, 6 Votes)
  • 6p-8p Eastern / 11p-1a GMT (14%, 5 Votes)
  • 12p-2p Eastern / 5p-7p GMT (8%, 3 Votes)
  • 8-10am Eastern / 1p-3p GMT (5%, 2 Votes)
  • 10am-12p Eastern / 3p-5p GMT (5%, 2 Votes)
  • 10p-12a Eastern / 3a-5a GMT (3%, 1 Votes)
  • 2a-4a Eastern / 7a-9a GMT (3%, 1 Votes)
  • 4a-6a Eastern / 9a-11a GMT (3%, 1 Votes)
  • 6a-8a Eastern / 11a-1p GMT (3%, 1 Votes)
  • 12a-2a Eastern / 5a-7a GMT (0%, 0 Votes)

Total Voters: 17

Loading ... Loading ...

If you need to convert the listed time to your time zone, please use thetimezoneconverter.com.

internal #RheumJC poll of #ACR16 abstracts

Uncategorized

Internal #RheumJC poll - choose as many as you would like

  • 3028 - A Single Infusion of Rituximab Delays the Onset of Arthritis in Subjects at High Risk of Developing RA. (10%, 5 Votes)
  • 911 - Efficacy and Safety of Tocilizumab in Patients with Giant Cell Arteritis: Primary and Secondary Outcomes from a Phase 3, Randomized, Double-Blind, Placebo-Controlled Trial. (10%, 5 Votes)
  • 1955 - Rituximab Versus Azathioprine to Maintain Remission of ANCA-Associated Vasculitides (MAINRITSAN): Follow-up at 60 Months (10%, 5 Votes)
  • 2987 - Comparison of Certolizumab Pegol Versus Adalimumab: 2 Year Efficacy and Safety Results from a Superiority, Investigator-Blind, Head-to-Head Study (8%, 4 Votes)
  • 1725 - Combination Therapy of Apremilast and Biologic Agent As a Safe Option of Psoriatic Arthritis and Psoriasis (6%, 3 Votes)
  • 3225 - Dual Cytokine Inhibition with ABT-122, a Tnf– and IL-17–Targeted Dual Variable Domain Immunoglobulin (DVD-Ig™): Results from a 24-Week Open-Label Extension Study in Patients with RA (6%, 3 Votes)
  • 86 - Optimizing the Efficiency of Patient Data Capture Using Smartphone Technology: Evaluation of the Correlation Between Promis Instruments for PRO Data Capture (6%, 3 Votes)
  • 1957 - No Increased Risk of Chronic Kidney Disease with Allopurinol Use (6%, 3 Votes)
  • 3169 - Diagnostic Value of Ultrasound for the Diagnosis of Gout in a Prospective Cross-Sectional Study (6%, 3 Votes)
  • 10L - Efficacy and Safety of Tofacitinib, an Oral JAK Inhibitor, in Patients with Active PsA and an Inadequate Response to TNF Inhibitors: OPAL Beyond, a RCT, Phase 3 Trial (4%, 2 Votes)
  • 559 - Comparison of MD-HAQ-Based and PROMIS 29-Based RAPID3 for Assessing RA Disease Activity (4%, 2 Votes)
  • 597 - Comparative Effectiveness of Different Anti-TNF Drugs As First Biological DMARD in RA: Results from the Nationwide Swedish Register 2010-2015 (4%, 2 Votes)
  • 604 - Sustained Efficacy/Comparable Safety/Immunogenicity after Transition to SB5 (an Adalimumab Biosimilar) Vs. Continuation of SB5 or Reference Adalimumab (Humira®) in Patients with RA (4%, 2 Votes)
  • 2983 - Efficacy and Safety of Tofacitinib, an Oral JAK Inhibitor, or Adalimumab in Patients with Active PsA and an Inadequate Response to Conventional Synthetic Dmards: A RCT Phase 3 Trial. (4%, 2 Votes)
  • 1586 - Efficacy and Safety of Baricitinib in Patients with Rheumatoid Arthritis and an Inadequate Response to Conventional DMARDs: A United States Subpopulation Analysis from Two Phase 3 Trials (2%, 1 Votes)
  • 2001 - Perioperative Use of Synthetic Disease-Modifying Anti-Rheumatic Drugs or Tumor Necrosis Factor α Inhibitors Does Not Associate with Increased Rates of Post-Operative Infections (2%, 1 Votes)
  • 969 - Safety and Efficacy of Subcutaneous Tocilizumab in Early Systemic Sclerosis: Results from the Open-Label Period of a Phase 2 Randomized, Controlled Trial (2%, 1 Votes)
  • 1047 - Negative Results of Antinuclear Antibody (ANA) Testing in Clinical Trials of Systemic Lupus Erythematosus (SLE) May be Due to Assay Variability. (2%, 1 Votes)

Total Voters: 7

Loading ... Loading ...

Real World RA Treatments: Using a 2nd anti-TNF or a non-anti-TNF after primary failure of 1st anti-TNF

Journal Club #14: Real World RA Treatments: Using a 2nd anti-TNF or a non-anti-TNF after primary failure of 1st anti-TNF

tnf-protein

Bonjour #RheumJC friends,

We’re pleased to announce our next journal club session will be Thursday, October 27th, discussing the JAMA article: Non–TNF-Targeted Biologic vs a Second Anti-TNF Drug to Treat Rheumatoid Arthritis in Patients With Insufficient Response to a First Anti-TNF Drug: A Randomized Clinical Trial by Dr. Jacques-Eric Gottenberg, et al.

Dr. Gottenberg, will be joining us for the first one-hour session.

Dr. Gottenberg (@jegotten) is a staff rheumatologist with the Department of Rheumatology, National Reference Center for Systemic Autoimmune Diseases, Strasbourg University Hospital, Université de Strasbourg, Strasbourg, France.

JAMA has graciously made Dr. Gottenberg’s article and the related article free to access for 48 hours beginning October 26th

If you’re new to this, take a look at our Intro to Twitter page or our Journal Club Getting Started Guide.

We strongly suggest using the website tchat.io as the best way to participate in the chat by typing in the #RheumJC hashtag to join the discussion.

As always:

  1. Please remember to try to stay on topic whenever possible.
  2. Be polite and courteous.
  3. Do not violate HIPAA.

We welcome suggestions for future articles for discussion. Please send your suggestions by Direct Message on Twitter to @RheumJC or email us at rheumjc@rheumjc.com.

Immune Checkpoint Inhibitor Induced Inflammatory Arthritis and Sicca Syndrome

Journal Club #13: Immune Checkpoint Inhibitor Induced Inflammatory Arthritis and Sicca Syndrome

screen-shot-2016-09-19-at-9-44-09-pm

Welcome back #RheumJC friends!

After enjoying a little summer break, #RheumJC is happy to announce our next journal club will be Thursday, September 29th.

We’ll be discussing the Annals of the Rheumatic Disease article Inflammatory arthritis and sicca syndrome induced by nivolumab and ipilimumab by Dr. Laura C Cappelli, et al.

We are also extremely pleased to that the author, Dr. Laura Cappelli, will be joining us for the first one-hour session.

Dr. Laura Cappelli (@cappelliMD) is a staff rheumatologist with Johns Hopkins Division of Rheumatology.

BMJ has graciously made Dr. Cappelli’s article and the accompanying editorial free to access from 22nd September to 6th October (until one week after the journal club).

If needed, take a look at our Intro to Twitter page or our Journal Club Getting Started Guide.

We strongly suggest using the website tchat.io as the best way to participate in the chat by typing in the #RheumJC hashtag to join the discussion.

As always:

  1. Please remember to try to stay on topic whenever possible.
  2. Be polite and courteous.
  3. Do not violate HIPAA.

We welcome suggestions for future articles for discussion. Please send your suggestions by Direct Message on Twitter to @RheumJC or email us at rheumjc@rheumjc.com.

Missed opportunities in the 2015 ACR guideline for RA treatment

Journal Club #12: Missed opportunities in the 2015 ACR guideline for RA treatment

shutterstock_19456234-600w

Greetings #RheumJC friends!

We’re tremendously excited to announce our next journal club will be Thursday, June 30th, 2016 discussing the Nature Reviews Rheumatology article: Rheumatoid arthritis: Missed opportunities in the 2015 ACR guideline for RA treatment by Dr. Ronald van Vollenhoven.

As usual, we will have two one-hour sessions:

Nature Reviews Rheumatology has graciously made Dr. van Vollenhoven’s article free to access from now until July 7, 2016 via the above link.

For reference, here is a link to the 2015 American College of Rheumatology guideline for the treatment of rheumatoid arthritis by Singh J., et al.

If needed, take a look at our Intro to Twitter page or our Journal Club Getting Started Guide.

We strongly suggest using the website tchat.io as the best way to participate in the chat by typing in the #RheumJC hashtag to join the discussion.

As always:

  1. Please remember to try to stay on topic whenever possible.
  2. Be polite and courteous.
  3. Do not violate HIPAA.

We welcome suggestions for future articles for discussion. Please send your suggestions by Direct Message on Twitter to @RheumJC or email us at rheumjc@gmail.com.

IL-6 Blockade with Tocilizumab for Scleroderma

Journal Club #11: IL-6 Blockade with Tocilizumab for Scleroderma

512px-Fibroblast_(BPAE)
Fibroblast image by Heiti Paves (Own work) [CC BY-SA 3.0], via Wikimedia Commons.

The next session of #RheumJC will be Thursday, June 2, 2016, discussing a recent article from The Lancet by Khanna, D., et al, looking at the role of IL–6 blockage in scleroderma, titled Safety and efficacy of subcutaneous tocilizumab in adults with systemic sclerosis (faSScinate): a phase 2, randomised, controlled trial.

This article is open access and can found on The Lancet or via PubMed.

*** We goofed! This article isn’t actually open access, but we’ll do a rundown of the article on Twitter during the #RheumJC session.***

We will again have two one-hour sessions, the first at 9pm GMT (4pm EST) and the second at 3am GMT (10pm EST).

If needed, take a look at our Intro to Twitter page or our Journal Club Getting Started Guide.

We strongly suggest using the website tchat.io as the best way to participate in the chat by typing in the #RheumJC hashtag to join the discussion.

As always:

  1. Please remember to try to stay on topic whenever possible.
  2. Be polite and courteous.
  3. Do not violate HIPAA.

We welcome suggestions for future articles for discussion. Please send your suggestions by Direct Message on Twitter to @RheumJC or email us at rheumjc@gmail.com.

Secukinumab (IL-17A blockage) in Psoriatic Arthritis

Journal Club #10: Secukinumab (IL-17A blockage) in Psoriatic Arthritis

shutterstock_296497013-600w

Greetings rheumatology friends! The next session of #RheumJC will be Thursday, May 5, 2016, where we will be discussing secukinumab, an anti-interleukin–17A monoclonal antibody that was recently FDA approved for the treatment of psoriatic arthritis. The article we’ll be discussing was published in October 2015 in the New England Journal of Medicine and is titled Secukinumab Inhibition of Interleukin–17A in Patients with Psoriatic Arthritis. We again expect a lively discussion about this new treatment option.

This article is open access and can found at this link: http://www.nejm.org/doi/full/10.1056/NEJMoa1412679

A direct link to the PDF is available here: http://www.nejm.org/doi/pdf/10.1056/NEJMoa1412679

We will again have two one-hour sessions, the first at 9pm GMT (4pm EST) and the second at 3am GMT (10pm EST).

If you are new to using Twitter, take a look at our Intro to Twitter page.

If you are participating in a Twitter journal club chat for the first time, please read our Getting Started Guide to get some tips on how to make the most of this session and not get too bogged down. Some additional pointers:

  1. Please remember to try to stay on topic whenever possible.
  2. Be polite and courteous.
  3. Do not violate HIPAA.

As always, we welcome suggestions for future articles for discussion. Please send your suggestions by Direct Message on Twitter to @RheumJC or email us at rheumjc@gmail.com.

The Link Between Periodontal Disease and Rheumatoid Arthritis

Journal Club #09: The Link Between Periodontal Disease and Rheumatoid Arthritis

teeth-header-600w

Greetings! The next session of #RheumJC will be on Thursday, March 31, 2016, where we will be discussing a recent meta-analysis looking at a potential environmental link between periodontal disease and rheumatoid arthritis titled “Hand to Mouth: A Systematic Review and Meta-Analysis of the Association between Rheumatoid Arthritis and Periodontitis” by Fuggle, NR, et al. This promises to be a lively discussion so we hope you can join.

This article is open access and can found at this link: http://journal.frontiersin.org/article/10.3389/fimmu.2016.00080/full

We will again have two one-hour sessions, the first at 9pm GMT (4pm EST) and the second at 3am GMT (10pm EST).

If you are new to using Twitter, take a look at our Intro to Twitter page.

If you are participating in a Twitter journal club chat for the first time, please read our Getting Started Guide to get some tips on how to make the most of this session and not get too bogged down. Some additional pointers:

  1. Please remember to try to stay on topic whenever possible.
  2. Be polite and courteous.
  3. Do not violate HIPAA.

As always, we welcome suggestions for future articles for discussion. Please send your suggestions by Direct Message on Twitter to @RheumJC or email us at rheumjc@gmail.com.